This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

David C. Anderson, MD; Robert Sherman, PhD
Department of Neurology Hennepin County Medical Center 701 Park Ave S Minneapolis, MN 55414

Arch Neurol. 1989;46(1):12-13.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Just prior to the publication of our article¹ describing experience with evoked potentials in a clinical treatment trial in multiple sclerosis, Nuwer et al² detailed their observations in another treatment trial. There is something to be learned by comparing the two. It is important at the onset, however, to understand that there were important differences between the two studies and in their results. On trial in the earlier study was the effectiveness of immunosuppressant therapies in retarding gradual deterioration in patients with chronic progressive multiple sclerosis. The study was planned over the long term so that the effects of slowing the immunopathologic process could be detected. Finally, the study demonstrated significant benefit of the program, both on clinical and electrophysiologic bases.

Our study, on the other hand, sought to corroborate earlier observations about short-term improvement related to hyperbaric oxygen treatment.¹ The protocol was planned to examine both . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?